Antiviral Effect, Safety, & Pharmacokinetics of once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-Naive Patients for 24 weeks as Combination Therapy with Pegylated Interferon-a 2a and Ribavirin
ID Number 08-1348
Principal Investigator(s)Douglas Dieterich
Department(s) or Division(s)
Liver Diseases
Description
The purpose of this study is to see how well the study drug, called BI 201335 NA, works and how safe it is to use daily in combination with the standard of care drugs, Pegasys® and Copegus®, in patients with the Hepatitis C Virus (HCV).
Contact Information
Douglas Dieterich, MD
douglas.dieterich@mountsinai.org
Recruiting Patients: No